Perspective presents interim results from Phase 1/2 trial of 212PbVMT-a-NET

Perspective Therapeutics (CATX) announced updated interim results from its ongoing Phase 1/2a clinical trial of 212PbVMT-alpha-NET in patients with unresectable or metastatic somatostatin receptor type 2 expressing neuroendocrine tumors are being presented as a poster presentation at the 2026 ASCO Gastrointestinal Cancers Symposium, taking place January 8-10 in San Francisco, CA. Interim results with a data cut-off date of December 10, 2025 formed the basis of the ASCO-GI update. The presentation includes safety data from 56 patients across three dose cohorts who have received at least one treatment of 212PbVMT-alpha-NET, and efficacy analysis from two patients in Cohort 1 and 23 of the patients in Cohort 2. Results with a data cut-off date of September 12, 2025 were previously presented at the European Society for Medical Oncology Congress 2025 in October 2025. At ESMO, the Company reported safety data on 55 patients across three dose cohorts who had received at least one treatment of 212PbVMT-alpha-NET and interim efficacy data for two patients in Cohort 1 and 23 patients in Cohort 2.